Methods and apparatus for intelligently providing power to a device
    41.
    发明授权
    Methods and apparatus for intelligently providing power to a device 有权
    用于智能地向设备提供电力的方法和装置

    公开(公告)号:US08661268B2

    公开(公告)日:2014-02-25

    申请号:US12840194

    申请日:2010-07-20

    IPC分类号: G06F1/00

    CPC分类号: G06F1/266

    摘要: Methods and apparatus for intelligently powering an electronic device are provided. In one embodiment of the invention, a systems management controller controls a power interface to intelligently negotiate power distribution with a peer, client, or a host device. The primary data path is unaffected by the system management controller communications. Various aspects of the present invention are demonstrated with respect to an exemplary implementation of a unified interface, consisting of an optical link (data path) and a USB link (power). As described, one exemplary embodiment of the invention provides a device with power at levels which are much increased over prior art USB solutions.

    摘要翻译: 提供了用于智能地为电子设备供电的方法和装置。 在本发明的一个实施例中,系统管理控制器控制功率接口以智能地协商与对等设备,客户端或主机设备的配电。 主数据路径不受系统管理控制器通信的影响。 关于由光链路(数据路径)和USB链路(电力)组成的统一接口的示例性实现来说明本发明的各个方面。 如所描述的,本发明的一个示例性实施例提供了一种具有比现有技术的USB解决方案大得多的功率的设备。

    Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
    45.
    发明授权
    Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists 有权
    通过组合Dll4拮抗剂和VEGF拮抗剂抑制肿瘤生长的治疗方法

    公开(公告)号:US08048418B2

    公开(公告)日:2011-11-01

    申请号:US12435030

    申请日:2009-05-04

    IPC分类号: A61K39/395 A61K38/16

    摘要: Disclosed is a therapeutic method for inhibiting development or growth of tumors that are resistant to the blockade of delta-like ligand 4 (Dll4), or vascular endothelial growth factor (VEGF), or to other therapeutic agents, by administering the combination of Dll4 antagonist and VEGF antagonist. The combined administration of these two agents, concurrently or sequentially, exhibits synergistic effects on blood vessel development and growth, thereby more effectively inhibiting the tumor growth than an administration of either agent alone. The Dll4 antagonist can be an anti-Dll4 antibody or antibody fragment capable of inhibiting the binding of Dll4 to a Notch receptor, or a fusion protein comprising the extracellular domain of Dll4 or a soluble Notch receptor, or a fragment thereof, fused to a multimerizing component. The VEGF antagonist can be a VEGF trap, anti-VEGF antibody or antibody fragment capable of inhibiting the binding of VEGF to a VEGF receptor.

    摘要翻译: 公开了通过施用Dll4拮抗剂的组合来抑制对阻滞δ-样配体4(Dll4)或血管内皮生长因子(VEGF)或其它治疗剂的抗性的肿瘤的发展或生长的治疗方法 和VEGF拮抗剂。 这两种试剂同时或相继地组合施用对血管发育和生长表现出协同作用,从而比单独施用任一试剂更有效地抑制肿瘤生长。 Dll4拮抗剂可以是能够抑制Dll4与Notch受体结合的抗Dll4抗体或抗体片段,或包含融合到多聚化的Dll4的细胞外结构域或其可溶性Notch受体或其片段的融合蛋白 零件。 VEGF拮抗剂可以是能够抑制VEGF与VEGF受体结合的VEGF陷阱,抗VEGF抗体或抗体片段。

    OFFLINE SHARING CAPABILITY FOR CLIENT APPLICATION
    47.
    发明申请
    OFFLINE SHARING CAPABILITY FOR CLIENT APPLICATION 有权
    客户应用的离线共享能力

    公开(公告)号:US20110252006A1

    公开(公告)日:2011-10-13

    申请号:US13164408

    申请日:2011-06-20

    IPC分类号: G06F17/30 G06F15/16

    摘要: Application Programming Interfaces (APIs) and UI modifications for existing applications are used to implement efficient methods for taking content offline with full synchronization, incremental synchronization, in the case of document libraries per-folder synchronization, and the like. The APIs provide support for synchronizing changes to attachments, the ability to download a document library's complete contents or only a list of the available documents, and read-only folder hierarchy replication in the case of document libraries. These abilities coupled with corresponding user interface features enable easier browsing and searching of large document library structures, making edits to those documents offline, being able to see an up-to-date version of those documents in a preview mode, and receiving reminders when offline edits remain on the local computer and need to be updated to a server.

    摘要翻译: 用于现有应用程序的应用程序编程接口(API)和UI修改用于实现高效的方法,用于在文件库每文件夹同步的情况下,完全同步,增量同步,脱机内容等。 API提供对同步更改附件,下载文档库完整内容或仅可用文档列表的能力以及文档库中只读文件夹层次结构复制的支持。 这些功能与相应的用户界面功能相结合,可以更轻松地浏览和搜索大型文档库结构,对这些文档进行离线编辑,能够以预览模式查看这些文档的最新版本,并在离线时接收提醒 编辑仍保留在本地计算机上,需要更新到服务器。

    Tapered Spiral Welded Structure
    48.
    发明申请
    Tapered Spiral Welded Structure 有权
    锥形螺旋焊接结构

    公开(公告)号:US20110179623A1

    公开(公告)日:2011-07-28

    申请号:US12693369

    申请日:2010-01-25

    IPC分类号: B23P11/00

    摘要: A method for creating a tapered spiral welded conical structure where the overall shape of the cone is first graphically slit axially and unwrapped, and then a series of construction arcs and lines are created to form the edge lines of a strip that can then be wrapped (rolled) to form a tapered conical structure. The edges of the spirally wound strip can be welded together, and a very large conical structure can thus be achieved. Various construction options are presented from a constant width strip to strip made from straight segments. Equations are given for the formation of the strips to enable those skilled in the art of spiral welded tubing to practice the invention.

    摘要翻译: 一种用于产生锥形螺旋焊接圆锥形结构的方法,其中锥体的整体形状首先以图形方式被轴向地切开和展开,然后创建一系列构造弧线和线以形成条带的边缘线, 轧制)以形成锥形锥形结构。 螺旋卷绕的条带的边缘可以焊接在一起,因此可以实现非常大的锥形结构。 从固定宽度的条带到由直线段制成的带状物呈现出各种构造选项。 给出条带形成的等式,以使得螺旋焊接管技术领域的技术人员能够实践本发明。

    THERAPEUTIC METHODS FOR INHIBITING TUMOR GROWTH WITH DLL4 ANTAGONISTS
    49.
    发明申请
    THERAPEUTIC METHODS FOR INHIBITING TUMOR GROWTH WITH DLL4 ANTAGONISTS 有权
    用DLL4拮抗剂抑制肿瘤生长的治疗方法

    公开(公告)号:US20090246199A1

    公开(公告)日:2009-10-01

    申请号:US12435030

    申请日:2009-05-04

    IPC分类号: A61K39/395 A61K38/16

    摘要: Disclosed is a therapeutic method for inhibiting development or growth of tumors that are resistant to the blockade of delta-like ligand 4 (Dll4), or vascular endothelial growth factor (VEGF), or to other therapeutic agents, by administering the combination of Dll4 antagonist and VEGF antagonist. The combined administration of these two agents, concurrently or sequentially, exhibits synergistic effects on blood vessel development and growth, thereby more effectively inhibiting the tumor growth than an administration of either agent alone. The Dll4 antagonist can be an anti-Dll4 antibody or antibody fragment capable of inhibiting the binding of Dll4 to a Notch receptor, or a fusion protein comprising the extracellular domain of Dll4 or a soluble Notch receptor, or a fragment thereof, fused to a multimerizing component. The VEGF antagonist can be a VEGF trap, anti-VEGF antibody or antibody fragment capable of inhibiting the binding of VEGF to a VEGF receptor.

    摘要翻译: 公开了通过施用Dll4拮抗剂的组合来抑制对阻滞δ-样配体4(Dll4)或血管内皮生长因子(VEGF)或其它治疗剂的抗性的肿瘤的发展或生长的治疗方法 和VEGF拮抗剂。 这两种试剂同时或相继地组合施用对血管发育和生长表现出协同作用,从而比单独施用任一试剂更有效地抑制肿瘤生长。 Dll4拮抗剂可以是能够抑制Dll4与Notch受体结合的抗Dll4抗体或抗体片段,或包含融合到多聚化的Dll4的细胞外结构域或其可溶性Notch受体或其片段的融合蛋白 零件。 VEGF拮抗剂可以是能够抑制VEGF与VEGF受体结合的VEGF陷阱,抗VEGF抗体或抗体片段。